Epithelial–mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways
Open Access
- 12 September 2016
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 36 (11) , 1546-1558
Abstract
Epithelial–mesenchymal transition (EMT) is regarded as a crucial contributing factor to cancer progression. Diverse factors have been identified as potent EMT inducers in ovarian cancer. However, molecular mechanism sustaining EMT of ovarian cancer cells remains elusive. Here we show that the presence of SOS1/EPS8/ABI1 complex is critical for sustained EMT traits of ovarian cancer cells. Consistent with the role of SOS1/EPS8/ABI1 complex as a Rac1-specific guanine nucleotide exchange factor, depleting Rac1 results in the loss of most of mesenchymal traits in mesenchymal-like ovarian cancer cells, whereas expressing constitutively active Rac1 leads to EMT in epithelial-like ovarian cancer cells. With the aid of clinically tested inhibitors targeting various EMT-associated signaling pathways, we show that only combined treatment of mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) and Src inhibitors can abolish constitutively active Rac1-led EMT and mesenchymal traits displayed by mesenchymal-like ovarian cancer cells. Further experiments also reveal that EMT can be induced in epithelial-like ovarian cancer cells by co-expressing constitutively active MEK1 and Src rather than either alone. As the activities of Erk and Src are higher in ovarian cancer cells with constitutively active Rac1, we conclude that Rac1 sustains ovarian cancer cell EMT through simultaneous activation of MEK1/2 and Src signaling pathways. Importantly, we demonstrate that combined use of MEK1/2 and Src inhibitors effectively suppresses development of intraperitoneal xenografts and prolongs the survival of ovarian cancer-bearing mice. This study suggests that cocktail of MEK1/2 and Src inhibitors represents an effective therapeutic strategy against ovarian cancer progression.Keywords
This publication has 50 references indexed in Scilit:
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expressionOncotarget, 2015
- The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusionsHuman Pathology, 2015
- Redox processes inform multivariate transdifferentiation trajectories associated with TGFβ-induced epithelial–mesenchymal transitionFree Radical Biology and Medicine, 2014
- Metastatic ovarian cancer cell malignancy is increased on soft matrices through a mechanosensitive Rho/ROCK pathwayJournal of Cell Science, 2014
- RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and MetastasisMolecular Cancer Therapeutics, 2013
- Epithelial–Mesenchymal Transition in Ovarian CarcinomaFrontiers in Oncology, 2012
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Expression Profiles of Genes Involved in Poor Prognosis of Epithelial Ovarian CarcinomaInternational Journal of Gynecological Cancer, 2009
- Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasionCancer Cell, 2003
- EPS8 and E3B1 transduce signals from Ras to RacNature, 1999